ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2730

Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting

William Tillett1,2, James Piercy3, Su Chen4 and Fabiana Ganz5, 1Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 2Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 3Adelphi Real World, Cheshire, United Kingdom, 4AbbVie, North Chicago, IL, 5Neuhofstrasse 23, AbbVie, Baar, Switzerland

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Patient Satisfaction, patient-reported outcome measures and psoriatic arthritis, Work Disability

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Patients (pts) with psoriatic arthritis (PsA) may experience temporary worsening of symptoms or disease flare, which can be painful enough to interfere with day-to-day activities. The impact of pt perception of severity of disease flare on work productivity, treatment satisfaction, and other pt-reported outcomes (PROs) has not been quantified in detail. The purpose of this analysis is to evaluate the perception of disease flares in pts with PsA and its impact on work productivity and treatment satisfaction in real world setting.

Methods:  Adelphi1 2014 Rheumatology Disease Specific Programme is a large multi-center, multi-country, cross-sectional survey of pts with a physician confirmed diagnosis of PsA. Pts filled out a self-completion survey providing an assessment of their symptoms (severity of disease and flaring), quality of life (QoL), and satisfaction with disease control. The self-assessment questionnaire also included pt-reported alternative Health Assessment Questionnaire-Disability Index (HAQ-DI, without aids and devices), Work Productivity and Activity Impairment–Specific Health Problem (WPAI-SHP), and treatment satisfaction. Statistical differences between the groups were evaluated using chi-square test (categorical variables) or analysis of variance (ANOVA, continuous variables).

Results:  Of the 341 PsA pts analyzed from the Adelphi database, 236 (69.2%) pts experienced temporary worsening of symptoms or disease flare. Among pts who reported experiencing a flare, mean age was 51 years and 54% were female. At survey, 126 (55.3%) pts reported experiencing moderate flare, while 53 (23.2%) and 49 (21.5%) experienced mild and severe flare, respectively. Pt-reported severity of last flare increased significantly with increasing perception of PsA severity at survey (P<0.001), at its worst (P<0.001), or before current treatment (P=0.003, Table). The severity of disease flare, as reported by pts, was negatively associated with the ability of pts to go to work and perform well at work (P<0.001) and perform daily tasks (P<0.001). The mean HAQ-DI (P<0.001) and WPAI (P<0.001) scores significantly worsened with increasing severity of disease flare perception. Of the pts reporting mild, moderate, and severe flares, 32 (64.0%), 72 (60.0%), and 26 (53.1%), respectively, were receiving biologic medicine. Pts’ satisfaction with the current treatment (P=0.002) was significantly lower with increasing severity of disease flare.

Conclusion:  Pt perception of PsA severity increased with the severity of pt-reported disease flare. Increasing severity of disease flare perception was associated with decreased work productivity, reduced ability to perform day-to-day activities, and less treatment satisfaction. Pts reporting moderate to severe disease flare experience significantly higher disease burden. References: 

  1. Anderson et al., Curr Med Res Opin., 2008; 24 (11):3063-72.


Disclosure: W. Tillett, AbbVie, Celgene, Pfizer, Novartis and UCB., 9; J. Piercy, Adelphi Real World, 3; S. Chen, AbbVie, 3,AbbVie, 1; F. Ganz, AbbVie, 3,AbbVie, 1.

To cite this abstract in AMA style:

Tillett W, Piercy J, Chen S, Ganz F. Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/impact-of-disease-flare-perception-on-work-productivity-and-treatment-satisfaction-in-patients-with-psoriatic-arthritis-in-real-world-setting/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-disease-flare-perception-on-work-productivity-and-treatment-satisfaction-in-patients-with-psoriatic-arthritis-in-real-world-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology